Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amcell Corp., Amgen deal

The Miltenyi technology uses an antibody bound to an iron dextran complex, which in turn binds

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE